Literature DB >> 15474251

Pre- and post-treatment patterns of human chorionic gonadotropin for early detection of persistence after a single dose of methotrexate for ectopic pregnancy.

Andrea Natale1, Massimo Candiani, Maurizio Barbieri, Chantal Calia, Maria P Odorizzi, Mauro Busacca.   

Abstract

OBJECTIVE: Given the great variability of human chorionic gonadotropin (HCG) levels after a single dose of methotrexate (MTX) for ectopic pregnancy, it remains complicated to identify cases undergoing persistence until a week from treatment. We evaluated whether pre-treatment patterns of HCG levels could be useful for an earlier detection of persistent trophoblast. STUDY
DESIGN: A retrospective study on 62 patients treated by a systemic single dose of methotrexate (50 mg/m(2)) for an ectopic pregnancy. Samples for HCG detection were obtained on days -2 and 0 before the therapy, on days +3, +7 and then weekly until values were undetectable. Patients were divided into three groups: Group U (up, meaning "increasing") and Group D (down, meaning "decreasing") when HCG levels on day 0 were respectively higher or lower than day -2 level of more than 20% and Group P (plateau) when the difference between day -2 HCG level and the level on day 0 was less than 20%.
RESULTS: All the patients of Group D underwent a complete resolution, with a percentage of 33.3% of cases who underwent an initial rise of HCG levels on day +3. The percentage of cases undergoing an initial rise of HCG levels in Group U patients was significantly higher than in Group P patients (60.0% versus 28.6%), but the resolution rate resulted similar in the two groups. For patients of Group P, an increase of HCG levels on day +3 was significantly correlated to the failure of the therapy. Indeed, comparing the cases with an immediate increase of HCG levels to the cases with immediate decrease of HCG levels on day +3, the persistence rate was 80% for the former and 12% for the latter (P < 0.0001).
CONCLUSION: An initial rise of HCG levels after the therapy does not seem to have a clinical relevance in Group D and Group U patients, it well correlates to trophoblastic persistence in Group P patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15474251     DOI: 10.1016/j.ejogrb.2004.04.017

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  7 in total

Review 1.  Interventions for tubal ectopic pregnancy.

Authors:  P J Hajenius; F Mol; B W J Mol; P M M Bossuyt; W M Ankum; F van der Veen
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Ectopic pregnancy comparison of different treatments.

Authors:  Fatmir Kopani; Arben Rrugia; Nikita Manoku
Journal:  J Prenat Med       Date:  2010-04

3.  Time to resolution of tubal ectopic pregnancy following methotrexate treatment: A retrospective cohort study.

Authors:  Marcus J Davenport; Anthea Lindquist; Fiona Brownfoot; Natasha Pritchard; Stephen Tong; Roxanne Hastie
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

4.  Interstitial pregnancy treated with a single-dose of systemic methotrexate: A successful management.

Authors:  Serena Corioni; Federica Perelli; Claudia Bianchi; Mauro Cozzolino; Luana Maggio; Giulia Masini; Maria Elisabetta Coccia
Journal:  J Res Med Sci       Date:  2015-03       Impact factor: 1.852

5.  The Effective Role of Adding Letrozole to Methotrexate in the Management of Tubal Ectopic Pregnancies, a Randomized Clinical Trial.

Authors:  Zahra Rezaei; Marjan Ghaemi; Elham Feizabad; Behnaz Ghavami; Firoozeh Akbari Asbagh; Fatemeh Davari Tanha; Mahbod Ebrahimi; Zahra Khalaj Sereshki
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

6.  The METEX study: methotrexate versus expectant management in women with ectopic pregnancy: a randomised controlled trial.

Authors:  Norah M van Mello; Femke Mol; Albert H Adriaanse; Erik A Boss; Antonius B Dijkman; Johannes Pr Doornbos; Mark Hans Emanuel; Jaap Friederich; Loes van der Leeuw-Harmsen; Jos P Lips; Evert Jp van Santbrink; Harold R Verhoeve; Harry Visser; Willem M Ankum; Fulco van der Veen; Ben W Mol; Petra J Hajenius
Journal:  BMC Womens Health       Date:  2008-06-19       Impact factor: 2.809

7.  Predictors of success of repeated injections of single-dose methotrexate regimen for tubal ectopic pregnancy.

Authors:  Geum Joon Cho; Sang Hoon Lee; Jin Woo Shin; Nak Woo Lee; Tak Kim; Hai Joong Kim; Kyu Wan Lee
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.